Iranian Journal of Allergy, Asthma and Immunology 2017. 16(1):28-38.

Anti-inflammatory Effects of Novel Thiazolidinone Derivatives as Bioactive Heterocycles on RAW264.7 Cells
Hossein Ghafoori, Mehrnaz Rezaei, Asadollah Mohammadi


The inhibition of the inducible nitric oxide synthase (iNOS), cyclooxygenase 2 (COX-2) and nuclear factor-κB (NF-κB) production are research targets of attract in the field of anti-inflammatory drug development. Therefore, this study was designed to investigate the anti-inflammatory effects of novel thiazolidinone derivatives using a cellular model of lipopolysaccharide (LPS)-stimulated murine macrophage RAW 264.7. In the present study, five new derivatives (A to E) of thiazolidinone were synthesized and screened for anti-inflammatory activities. Cell viability of LPS-stimulated RAW 264.7 macrophages clearly decreased in >55 μg/mL of synthesized A-E compounds especially in the presence of C; therefore, up to 50 μg/mL of compounds were selected for the subsequent analysis. A majority of these compounds showed significant inhibition on the production of NO in LPS-stimulated macrophages in a dose-dependent manner. Compounds B and D (10-50 μg/mL) significantly inhibited LPS-induced NF-κB (p65) production in a dose-dependent manner. The effects of B and D on iNOS and COX-2 mRNA and protein expression in LPS-stimulated RAW 264.7 cells were detected by real time-PCR and western blot. B derivative significantly suppressed the iNOS and COX-2 mRNA level and as well as protein expression. Taken together, these results reveal that compound B as new thiazolidinone derivative decreased expression of the inflammatory-related signals (NO, iNOS and COX-2) through regulation of NF-κB; hence, this compound could be suggested as a novel therapeutic strategy for inflammation-associated disorders.


Anti-inflammatory effects; COX-2; iNOS; NF-κB (p65); Thiazolidinone

Full Text:



1.   Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006; 124(2):263-6.

2.   Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420(6917):860-7.

3. Moss  SF,  Blaser  MJ.  Mechanisms  of  disease: inflammation and the origins of cancer. Nat Clin Pract Oncol 2005; 2(2):90-7.

4.   Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, et al. NF-kB functions as a tumour promoter in inflammation-associated       cancer.       Nature       2004;431(7007):461-6.

5.   Lee HJ, Hyun E-A, Yoon WJ, Kim BH, Rhee MH, Kang HK, et al. In vitro anti-inflammatory and anti-oxidative effects of Cinnamomum camphora extracts. JJ Ethnopharmacol 2006; 103(2):208-16 .

6.   Roumen RMH, Redl H, Schlag G, Zilow G, Sandtner W,Koller W, et al. Inflammatory mediators in relation to the development of multiple organ  failure in patients after severe blunt trauma. Crit Care Med 1995; 23(3):474-80.

7.   Epstein FH, Barnes PJ, Karin  M. Nuclear factor- B a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336(15):1066-71.

8.   Ghosh S, Karin M. Missing pieces in the NF-kB puzzle.Cell 2002; 109(2):S81-S96.

9.   Hayden MS, Ghosh S. Signaling to NF-kB. Genes Dev2004; 18(18):2195-224.

10. Viatour   P,   Merville   M-P,   Bours   V,   Chariot   A.Phosphorylation of NF-kB and proteins implications in cancer  and  inflammation.  Trends  Biochem  Sci  2005;30(1):43-52.

11. Sacca    R,    Cuff    CA,    Ruddle    NH.    Mediators    of inflammation. Curr Opin Immunol 1997; 9(6):851-7.

12. Surh YJ, Chun KS, Cha H-H, Han SS, Keum YS, ParkKK, et al. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through  suppression  of  NF-kB  activation.  Mutat  Res2001; 480:243-68.

13. Larsen  GL,  Henson  PM.  Mediators  of  inflammation.Annu Rev Immunol 1983; 1(1):335-59.

14. Ghosh S, May MJ, Kopp EB. NF-kB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998; 16(1):225-60.

15. Aggarwal  BB,  Shishodia  S,  Sandur  SK,  Pandey  MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol 2006; 72(11):1605-21.

16. Allavena P, Garlanda C, Borrello MG, Sica A, Mantovani A. Pathways connecting inflammation and cancer. Curr Opin Genet Dev 2008; 18(1):3-10.

17. Nathan   C.   Nitric   oxide   as   a   secretory  product   of mammalian cells. FASEB J 1992; 6(12):3051-64.

18. MacMicking  J,  Xie  Q-w,  Nathan  C.  Nitric  oxide  and macrophage    function.    Annu    Rev    Immunol    1997;15(1):323-50.

19. Soslow  RA,  Dannenberg  AJ,  Rush  D,  Woerner  BM, Khan  KN,  Masferrer  J,  et  al.  COX-2  is  expressed  in human   pulmonary,   colonic,   and   mammary   tumors. Cancer 2000; 89(12):2637-45.

20. Gupta RA, DuBois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001; 1(1):11-21.

21. Hawkey     CJ.     COX-2     inhibitors.     Lancet    1999;353(9149):307-14.

22. Psaty BM, Furberg CD. COX-2 inhibitors lessons in drug safety. N engl J med 2005; 352(11):1133-5.

23. Tabas I, Glass CK. Anti-inflammatory therapy in chronic disease:  challenges  and  opportunities.  Science  2013;339(6116):166-72.

24. Portenoy  RK,  Lesage  P.  Management  of  cancer  pain.Lancet 1999; 353(9165):1695-700.

25. Beers MH. Explicit  criteria for determining potentially inappropriate medication use by the elderly: an update. Arch Intern Med 1997; 157(14):1531-6.

26. Martins  P,  Jesus  J,  Santos  S,  Raposo  LR,   Roma- Rodrigues C, et al. Heterocyclic Anticancer Compounds: Recent Advances and the Paradigm Shift towards the Use of  Nanomedicine’s  Tool  Box.  Molecules  2015;  20:16852-16891

27. Jain  AK,  Vaidya  A,  Ravichandran  V,  Kashaw  SK, Agrawal RK. Recent developments and biological activities of thiazolidinone derivatives: A review. Bioorg Med Chem 2012; 20(11):3378-95.

28. Jain VS, Vora DK, Ramaa CS. Thiazolidine-2, 4-diones: Progress towards multifarious applications. Bioorg Med Chem 2013; 21(7):1599-620.

29. Abhinit M, Ghodke M, Pratima NA. Exploring potential of 4-thiazolidinone: a brief review. Int J Pharm Pharm Sci 2009; 1(1):47-64.

30. Hu J, Wang Y, Wei X, Wu X, Chen G, Cao G, et al.Synthesis  and  biological  evaluation  of  novel thiazolidinone derivatives as potential anti-inflammatory agents. Eur J Med Chem 2013; 64:292-301.

31. Sharma A, Kumar V, Jain S, Sharma PC. Thiazolidin-4- one and hydrazone derivatives of capric acid as possible anti-inflammatory, analgesic and hydrogen peroxide- scavenging  agents.  J  Enzyme  Inhib  Med  Chem  2011;26(4):546-52.

32. Ottana R, Mazzon E, Dugo L, Monforte F, Maccari R, Sautebin L, et al. Modeling and biological evaluation of 3-(1, 2-ethanediyl) bis [2-(4-methoxyphenyl)-thiazolidin-4-one], a new synthetic cyclooxygenase-2 inhibitor. Eur J Pharmacol 2002; 448(1):71-80.

33. Mohammadi   A,   Ghafoori   H,   Ghalami-Choobar   B, Rohinejad R. Synthesis, solvatochromic properties and biological evaluation of some novel azo-hydrazone tautomeric  dyes.  Journal  of  Molecular  Liquids  2014;198:44-50.

34. Mohammadi   A,   Safarnejad   M.   Synthesis,   structural characterization and tautomeric properties of some novel bis-azo  dyes  derived  from  5-arylidene-2,  4- thiazolidinone. Spectrochim Acta A Mol  Biomol Spectrosc 2014; 126:105-11.

35. Berridge MV, Herst PM, Tan AS. Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction. Biotechnol Annu Rev 2005; 11:127-52.

36. Kim HK, Cheon BS, Kim YH, Kim SY, Kim HP. Effects of naturally occurring flavonoids on nitric oxide production in the macrophage cell line RAW 264.7 and their structure activity relationships. Biochem Pharmacol 1999; 58(5):759-65.

37. Zor T, Selinger Z. Linearization of the Bradford protein assay  increases  its  sensitivity:  theoretical  and experimental studies. Anal Biochem 1996; 236(2):302-8.

38. Nathan  C.  Points  of  control  in  inflammation.  Nature 2002; 420(6917):846-52.

39. Makarov SS. NF- B as a therapeutic target in chronic inflammation:  recent advances.  Mol Med  Today 2000;6(11):441-8.

40. Yamamoto  Y,  Gaynor  RB.  Therapeutic  potential  of inhibition  of  the  NF-kB  pathway  in  the  treatment  of inflammation and cancer. J Clin Invest 2001; 107(2):135-42.

41. Hotamisligil GkS. Inflammation and metabolic disorders.Nature 2006; 444(7121):860-7.

42. Bhatti  RS,  Shah  S,  Krishan  P,  Sandhu  JS.  Recent Pharmacological Developments on Rhodanines and 2, 4- Thiazolidinediones. Int J Med Chem 2013; 2013:793260.

43. Ohmori  Y,  Hamilton  TA.  Requirement  for  STAT1  in LPS-induced gene expression in macrophages. J Leukoc Biol 2001; 69(4):598-604.

44. Rius   J,   Guma   M,   Schachtrup   C,   Akassoglou   K, Zinkernagel AS, Nizet V, et al. NF-k B links innate immunity to the hypoxic response through transcriptional regulation  of  HIF-1.  Nature  2008;  453(7196):807-11.



  • There are currently no refbacks.

Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.